DeepMed Research

FOX CHASE CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1904-01-01

Employees: -

Market Cap: -

Website: http://www.foxchase.org

Clinical Trials

A Study of Pembrolizumab in Combination With Epacadostat in Women With Recurrent/Metastatic Endometrial Carcinoma

Phase 2

Withdrawn

Conditions: Recurrent/ Metastatic Endometrial Carcinoma

Interventions: Drug: Epacadostat + pembrolizumab

First Posted Date: 2017-10-16

Last Posted Date: 2018-10-09

Lead Sponsor: Fox Chase Cancer Center

Registration Number: NCT03310567

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy

Phase 2

Terminated

Conditions: Non Small Cell Lung Cancer Stage IIIB

Interventions: Biological: Nivolumab
Drug: Nivolumab+Gemcitabine

First Posted Date: 2017-10-05

Last Posted Date: 2020-10-28

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 3

Registration Number: NCT03302247

Locations: 🇺🇸
Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States

Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

Recruiting

Conditions: Renal Cell Carcinoma
Urothelial Carcinoma
Bladder Cancer
Ureter Cancer
Urethral Cancer

Interventions: Biological: Immune checkpoint inhibitor targeting PD1

First Posted Date: 2017-09-25

Last Posted Date: 2025-01-10

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 16

Registration Number: NCT03291028

Locations: 🇺🇸
Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States

VM110 in Detection of Microscopic Tumors: A Phase I Study

Phase 1

Terminated

Conditions: Pancreatic Cancer
Ovarian Cancer

Interventions: Combination Product: Agent VM110 and laproscopic infra-red probe

First Posted Date: 2017-09-18

Last Posted Date: 2020-04-07

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 1

Registration Number: NCT03286062

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma

Phase 2

Active, not recruiting

Conditions: Urothelial Carcinoma

Interventions: Drug: Atezolizumab
Drug: Guadecitabine

First Posted Date: 2017-06-07

Last Posted Date: 2021-11-04

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 21

Registration Number: NCT03179943

Locations: 🇺🇸
USC Norris Hospital and Clinics, Los Angeles, California, United States
🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Trial Using Octreotide to Enhance Liver Recovery After Hepatectomy

Phase 2

Terminated

Conditions: Major Liver Resection

Interventions: Drug: Octreotide
Other: Placebo

First Posted Date: 2017-06-07

Last Posted Date: 2024-02-14

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 23

Registration Number: NCT03179995

Locations: 🇺🇸
Temple University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Impact of Ribociclib on Head and Neck Squamous Cell Cancer

Early Phase 1

Terminated

Conditions: Squamous Cell Carcinoma of the Head and Neck

Interventions: Drug: Ribociclib

First Posted Date: 2017-06-07

Last Posted Date: 2019-02-25

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 1

Registration Number: NCT03179956

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

SMART Project in Preventing Skin Cancer

Not Applicable

Completed

Conditions: Skin Carcinoma

Interventions: Other: Questionnaire Administration
Behavioral: Compliance Monitoring
Other: Health Telemonitoring

First Posted Date: 2017-06-06

Last Posted Date: 2018-08-01

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 114

Registration Number: NCT03177057

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma

Phase 1

Active, not recruiting

Conditions: Renal Cell Carcinoma

Interventions: Drug: Nivolumab
Drug: Axitinib

First Posted Date: 2017-06-01

Last Posted Date: 2024-10-26

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 98

Registration Number: NCT03172754

Locations: 🇺🇸
Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
US Oncology and Hematology, Albany, New York, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

and more 1 locations

Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer

Phase 2

Active, not recruiting

Conditions: HER2-positive Breast Cancer

Interventions: Drug: Atezolizumab
Drug: Paclitaxel
Drug: Trastuzumab
Drug: Pertuzumab

First Posted Date: 2017-04-24

Last Posted Date: 2025-01-10

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 16

Registration Number: NCT03125928

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy